IPO

Glenmark Life Sciences Limited IPO

Mainboard

Pharmaceuticals & Drugs

Listed On: Aug 6, 2021 at ₹ 750.0(NSE)

₹ 14400 /20 Shares

Check Allotment

27 Jul, 2021

Open Date

29 Jul, 2021

Close Date

03 Aug, 2021

Allotment Date

06 Aug, 2021

Listing Date
Price Summary

Last Closing

1,086.00 (50.83%)

52 Week High

1,335.10

52 Week Low

676.50

Last Update

17-Jan-2025 3:30 PM
IPO Issue Details
  • Issue Price ₹695-720 per equity share
  • Face Value ₹2 Per Equity Share 
  • Issue Price 1513.60 Crore; 1060 Crore Fresh Issue + 453.60 Crore Offer for Sale of 63,00,000 Shares
  • Listing at BSE, NSE
  • List Price 750.0(NSE)
  • Listing Date 2021-08-06
  • Lead Manager BoA Merrill Lynch, BOB Capital Markets Limited, DAM Capital Advisors Ltd (Formerly IDFC Securities Ltd), Goldman Sachs (India) Securities Private Limited, Kotak Mahindra Capital Company Limited, SBI Capital Markets Limited
  • Registrar KFintech Private Limited
IPO Details
  • Retail Portion 35%
IPO Documents
DRHP
RHP
IPO Details


The IPO of is priced at ₹695-720 per equity share, which has a face value of ₹2 Per Equity Share  each, IPO bidding starts from Jul 27, 2021 and ends on Jul 29, 2021. The allotment for IPO will be finalized on Aug 3, 2021. IPO will be listed on BSE, NSE, with a tentative listing date fixed as Aug 6, 2021. The company shall list its equity shares on the BSE, NSE. KFintech Private Limited is the registrar of the issue.

The book-running lead manager for the IPO is/are BoA Merrill Lynch, BOB Capital Markets Limited, DAM Capital Advisors Ltd (Formerly IDFC Securities Ltd), Goldman Sachs (India) Securities Private Limited, Kotak Mahindra Capital Company Limited, SBI Capital Markets Limited.


The IPO sets its price band at 695-720 for each share. A single application for Glenmark Life Sciences Limited IPO must contain at least 20 shares.

Read More
IPO Subscription Analysis And Details
Retail
15.00x
QIB
37.30x
NII
125.62x
Total
45.08x
As on QIB NII Retail Total
Shares Offered / Reserved 42,42,379 32,32,770 75,43,130 1,50,18,279
Day 1 27-07-20 05:00 PM
0.00 x 0.85 5.17 x 2.78 x
Day 2 28-07-20 05:00 PM
1.40 x 3.48 9.51 x 5.90 x
Day 3 29-07-20 05:00 PM
37.30 x 125.62 15.00 x 45.08 x
Total No of Applications
3950392
Subscription on the basis of Applications
10.74
Valuations
Earnings Per Share (EPS) ₹32.61/-
P/E Ratio 25.13
RoNW 46.71%
Net Asset Value (NAV) - As on 31.03.21 ₹69.83
Company Financials
In Crs.
In Cr.
31-Mar-21 31-Mar-20 31-Mar-19
Assets 1,997.07 1,725.60 1,475.39
Revenue 1,885.97 1,549.30 886.86
Profit After Tax 351.58 313.09 195.59
About Company

Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.

Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.

Read More
- Promoter(s)

Glenmark Pharmaceuticals Limited

Pre Issue Share Holding : 100%

Post Issue Share Holding : 82.84%

IPO - Issue Objectives
1

To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.

2

To finance capital expenditure requirements.

3

To meet general corporate purposes.

IPO - Anchor Investors

Glenmark Life Sciences mobilises Rs 454 crore from anchor investors ahead of IPO

HSBC Global Investment Funds, Government Pension Fund Global, Oaktree Emerging Markets Equity Fund LP, Copthall Mauritius Investment Ltd -ODI account, Societe Generale-ODI, Kuber India Fund and Reliance General Insurance Company are among the anchor investors.

IPO - Peers Comparison
P/B Ratio P/E Ratio RoNW Revenue(in Cr.)
Glenmark Lifesciences Limited 10.31 25.13 46.71% 1,859.76
Divis Laboratories Limited 12.95 61.40 210% 7,031.96
Laurus Labs Limited 22.06 77.45 15.56% 4,835.86
Shilpa Medicare Limited 7.15 42.08 17.00% 931.27
Aarti Drugs Limited 5.12 287.45 1.78% 2,159.31
Solara Active Pharma Sciences Limited 6.85 46.59 14.69% 1,645.65